Sep 3
|
Retail investors account for 52% of Omeros Corporation's (NASDAQ:OMER) ownership, while institutions account for 43%
|
Aug 7
|
Omeros: Q2 Earnings Snapshot
|
Aug 7
|
Omeros Corporation Reports Second Quarter 2024 Financial Results
|
Aug 5
|
Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
|
May 16
|
Q1 2024 Omeros Corp Earnings Call
|
May 16
|
Omeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ...
|
May 15
|
Omeros Corporation Reports First Quarter 2024 Financial Results
|
May 10
|
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
|
May 9
|
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
|
Apr 2
|
Q4 2023 Omeros Corp Earnings Call
|
Apr 2
|
Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript
|
Apr 1
|
Omeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial Results
|
Apr 1
|
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
|
Mar 27
|
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
|
Mar 17
|
Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade
|
Feb 1
|
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
|
Jan 10
|
Brian's Big Idea on Biotech
|
Nov 6
|
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
|
Nov 3
|
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
|
Nov 2
|
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
|